The Korean Journal of Medicine

  • 제79권1호
  • /
  • Pages.1-7
  • /
  • 2010
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지

급성 폐손상과 급성 호흡곤란 증후군의 내과적 치료

Nonventilatory medical treatments for acute respiratory distress syndrome and acute lung injury

  • 손장원 (한양대학교 의과대학 내과학교실)
  • Sohn, Jang-Won (Department of Internal Medicine, Hanyang University College of Medicine)
  • 발행 : 2010.07.01
⟨ 이전 논문 다음 논문 ⟩

초록

Over the past decade, the ventilator management for acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) have yielded improved outcomes. However, studies of the pharmacologic management of ARDS and ALI have been less effective. ARDS/ALI is a heterogeneous disease entity. Although most drug trials in ARDS or ALI have been demonstrated to be ineffective in improving outcomes, some studies suggest that targeting treatments at subgroups of patients may be beneficial. Corticosteroids have good short-term effects when given sooner than 2 weeks. Surfactant may be beneficial in direct lung injury patients. Anticoagulants may have improved outcomes in the severe patients with vascular disease. Recently, ARDS Networks reported the 'conservative fluid management strategy'. This promising fluid strategy showed beneficial effect on outcomes without serious complications. This article reviews the recent research on the Nonventilatory pharmacologic managements for patients with ARDS/ALI.

키워드

참고문헌

  1. Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM, Scales DC, Stather DR, Li A, Jones A, Gattas DJ, Hallett D, Tomlinson G, Stewart TE, Ferguson ND. Has mortality from acute respiratory distress syndrome decreased over time? A systematic review. Am J Respir Crit Care Med 179:220-227, 2009 https://doi.org/10.1164/rccm.200805-722OC
  2. Spragg RG, Lewis JF, Walmrath HD, Johannigman J, Bellingan G, Laterre PF, Witte MC, Richards GA, Rippin G, Rathgeb F, Hafner D, Taut FJ, Seeger W. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 351:884-892, 2004 https://doi.org/10.1056/NEJMoa033181
  3. Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, Jacobs BR, Jefferson LS, Conaway MR, Egan EA; Pediatric Acute Lung Injury and Sepsis Investigators. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 293;470-476, 2005 https://doi.org/10.1001/jama.293.4.470
  4. Taut FJ, Rippin G, Schenk P, Findlay G, Wurst W, Häfner D, Lewis JF, Seeger W, Günther A, Spragg RG. A search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute). Chest 134:724-732, 2008 https://doi.org/10.1378/chest.08-0362
  5. Zeiher BG, Artigas A, Vincent JL, Dmitrienko A, Jackson K, Thompson BT, Bernard G; STRIVE Study Group. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med 32:1695-1702, 2004 https://doi.org/10.1097/01.CCM.0000133332.48386.85
  6. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, Thompson BT, Ancukiewicz M; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 354:1671-1684, 2006 https://doi.org/10.1056/NEJMoa051693
  7. Agarwal R, Nath A, Aggarwal AN, Gupta D. Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta-analysis. Respirology 12:585-590, 2007 https://doi.org/10.1111/j.1440-1843.2007.01060.x
  8. Meduri GU, Marik PE, Chrousos GP, Pastores SM, Arlt W, Beishuizen A, Bokhari F, Zaloga G, Annane D. Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 34:61-69, 2008 https://doi.org/10.1007/s00134-007-0933-3
  9. Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. Br Med J 336:1006-1009, 2008 https://doi.org/10.1136/bmj.39537.939039.BE
  10. Tang BM, Craig JC, Eslick GD, Seppelt I, McLean AS. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: review and meta-analysis. Crit Care Med 37:1594-1603, 2009 https://doi.org/10.1097/CCM.0b013e31819fb507
  11. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001 https://doi.org/10.1056/NEJM200103083441001
  12. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, Tidswell M, Siegel MD, Soto G, Peterson MW, Chesnutt MS, Phillips C, Weinacker A, Thompson BT, Eisner MD, Matthay MA. Randomized clinical trial of activated protein c for the treatment of acute lung injury. Am J Respir Crit Care Med 178:618-623, 2008 https://doi.org/10.1164/rccm.200803-419OC
  13. Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, Zwingelstein C, Percell S, Shu V, Leighton A, Creasey AA. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 29:2081-2089, 2001 https://doi.org/10.1097/00003246-200111000-00007
  14. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. Br Med J 334:779-786, 2007 https://doi.org/10.1136/bmj.39139.716794.55
  15. Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 173:281-287, 2006 https://doi.org/10.1164/rccm.200508-1302OC
  16. Matthay MA, Brower R, Thompson BT, Schoenfeld D, Eisner MD, Carson S, Moss M, Douglas I, Hite D, MacIntyre N, Liu KD. Randomized, placebo-controlled trial of an aerosolized beta-2 adrenergic agonist (albuterol) for the treatment of acute lung injury. Am J Respir Crit Care Med 179:A2166, 2009
  17. ARDS Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354:2564-2575, 2006 https://doi.org/10.1056/NEJMoa062200
  18. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296-327, 2008 https://doi.org/10.1097/01.CCM.0000298158.12101.41
  19. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350:2247-2256, 2004 https://doi.org/10.1056/NEJMoa040232
  20. Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, Bernard GR. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med 33:1681-1687, 2005 https://doi.org/10.1097/01.CCM.0000171539.47006.02
  21. American Thoracic Society. Evidence-based colloid use in the critically ill: ATS consensus statement. Am J Respir Crit Care Med 170:1247-1259, 2004 https://doi.org/10.1164/rccm.200208-909ST
  22. Kreymann KG, Berger MM, Deutz NEP, et al. ESPEN Guidelines on enteral nutrition: Intensive care. Clin Nutr 25:210-223, 2006 https://doi.org/10.1016/j.clnu.2006.01.021
  23. Marik PE, Zaloga GP. Early enteral nutrition in acute ill patients: A systematic review. Crit Care Med 29:2264-2270, 2001 https://doi.org/10.1097/00003246-200112000-00005
  24. Simpson F, Doig GS. Parenteral vs. enteral nutrition in the critically ill patients: a meta-analysis trials using the intention to treat principle. Intensive Care Med 31:12-23, 2005 https://doi.org/10.1007/s00134-004-2511-2
  25. Pontes-Arruda A, Demichele S, Seth A, Singer P. The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data. J Parenter Enteral Nutr 32:596-605, 2008 https://doi.org/10.1177/0148607108324203
  26. Marik PE, Zaloga GP. Immunolonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med 34:1980-1990, 2008 https://doi.org/10.1007/s00134-008-1213-6